Fresenius Kabi Austria GmbH
UkraineAll drugs from this manufacturer
-
The drug is used for the parenteral (intravenous) administration of amino acids in severe forms of hepatic insufficiency, with or without hepatic encephalopathy, if the patient cannot or is unable to receive nutrition via the mouth or intestines.
Dosage form: solution for infusion
Active substance Dosage l-isoleucine 10.4 g/L l-leucine 13.09 g/L l-lysine 6.88 g/l l-methionine 1.1 g/L n-acetyl-l-cysteine 0.7 g/l l-phenylalanine 0.88 g/L l-threonine 4.4 g/L l-tryptophan 0.7 g/l l-valine 10.08 g/L l-arginine 10.72 g/L l-histidine 2.8 g/L glycine 5.82 g/L l-alanine 4.64 g/L l-proline 5.73 g/L l-serine 2.24 g/l acetic acid 4.42 g/L ATC: B05BA01
-
The drug is used as a component of parenteral (intravenous) nutrition for patients who cannot or cannot effectively be fed via the intestine. It contains amino acids necessary for metabolic processes and protein synthesis.
Dosage form: solution for infusion
Active substance Dosage l-alanine 14.00 g/L l-arginine 12.00 g/L l-valine 6.20 g/L l-histidine 3.00 g/L glycine 11.00 g/L l-leucine 7.40 g/l l-lysine 6.60 g/l l-isoleucine 5.00 g/L l-methionine 4.30 g/l l-serine 6.50 g/L taurine 1.00 g/L l-proline 11.20 g/L l-tyrosine 0.40 g/L l-threonine 4.40 g/l l-tryptophan 2.00 g/l l-phenylalanine 5.10 g/l ATC: B05BA01
-
The drug is used as a component of parenteral (intravenous) nutrition for patients who cannot or cannot effectively be fed via the digestive tract. It is used in combination with energy sources such as glucose or lipid emulsions.
Dosage form: solution for infusion
Active substance Dosage l-alanine 25.00 g/L l-arginine 20.00 g/L l-valine 5.50 g/l l-histidine 7.30 g/L glycine 18.50 g/L l-leucine 8.90 g/l l-lysine 11.10 g/L l-isoleucine 5.20 g/L l-methionine 3.80 g/l l-serine 9.60 g/L taurine 2.00 g/l l-proline 17.00 g/L l-tyrosine 0.40 g/L l-threonine 8.60 g/l l-tryptophan 1.60 g/l l-phenylalanine 5.50 g/l ATC: B05BA01
-
The drug is used for partial parenteral (intravenous) nutrition of premature infants, neonates, and young children.
Dosage form: solution for infusion
Active substance Dosage arginine 7.5 g/l leucine 13 g/l isoleucine 8 g/L methionine 3.12 g/l phenylalanine 3.75 g/l alanine 9.3 g/L proline 9.71 g/L valine 9 g/L threonine 4.4 g/L lysine 8.51 g/L glycine 4.15 g/l histidine 4.76 g/l serine 7.67 g/L tyrosine 4.2 g/L tryptophan 2.01 g/L cysteine 0.52 g/L malic acid 2.62 g/L taurine 0.4 g/L ATC: B05BA01
-
The drug is used for parenteral (intravenous) nutrition of patients with impaired renal function, acute or chronic renal failure (including during dialysis), as well as in cases where conventional oral or enteral nutrition is impossible or insufficient.
Dosage form: solution for infusion
Active substance Dosage isoleucine 5.8 g/L leucine 12.8 g/L lysine 12 g/L methionine 2 g/L phenylalanine 3.5 g/l threonine 8.2 g/L tryptophan 3 g/L valine 8.7 g/L arginine 8.2 g/L histidine 9.8 g/L alanine 6.2 g/L cysteine 0.4 g/L glycine 5.305 g/L proline 3 g/L serine 7.6 g/l tyrosine 0.6 g/L glycyltyrosine 3.155 g/l ATC: B05BA01
-
The drug is used for the induction of general anesthesia in adults and children, as well as for the sedation of patients in intensive care units or during diagnostic and surgical procedures.
Dosage form: emulsion for injection or infusion
Active substance Dosage propofol 10 mg/ml ATC: N01AX10
-
The drug is used for the induction of general anesthesia in adults and children, as well as for the sedation of patients in intensive care units or during diagnostic and surgical procedures.
Dosage form: emulsion for injection or infusion
Active substance Dosage propofol 20 mg/ml ATC: N01AX10
-
The drug is used as a source of energy and essential fatty acids (including omega-3) for patients receiving parenteral nutrition when normal oral or enteral feeding is impossible, insufficient, or contraindicated.
Dosage form: emulsion, for infusion
Active substance Dosage refined soybean oil 60 g/l medium chain triglycerides 60 g/l refined olive oil 50 g/L purified fish oil 30 g/L ATC: B05BA02